TP-05 is under clinical development by Tarsus Pharmaceuticals and currently in Phase I for Malaria. According to GlobalData, Phase I drugs for Malaria have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TP-05’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TP-05 overview
Lotilaner is under development for the prevention of lyme disease and community malaria reduction. It is administered through oral route as tablets. It targets parasite-specific GABA-Cl channels.
Tarsus Pharmaceuticals overview
Tarsus Pharmaceuticals is a biopharmaceutical company that is involved in development and commercialization of therapeutics related to eye care. It is developing novel therapeutics for treatment of blepharitis which is caused by the infestation of Demodex mites. The company having the product pipeline for Meibomian Gland Disease, Rosacea, Lyme Disease and Malaria. The company is headquartered in Irvine, California, the US.
For a complete picture of TP-05’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.